Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
33.38
+0.43 (1.31%)
Jan 22, 2026, 1:22 PM EST - Market open
Genmab Employees
Genmab had 2,681 employees as of September 30, 2025. The number of employees increased by 46 or 1.75% compared to the same quarter last year.
Employees
2,681
Change
46
Growth
1.75%
Revenue / Employee
$1,434,416
Profits / Employee
$590,552
Market Cap
20.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 2,681 | 46 | 1.75% |
| Jun 30, 2025 | 2,639 | 113 | 4.47% |
| Mar 31, 2025 | 2,638 | 352 | 15.40% |
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Sep 30, 2024 | 2,635 | 503 | 23.59% |
| Jun 30, 2024 | 2,526 | 511 | 25.36% |
| Mar 31, 2024 | 2,286 | 440 | 23.84% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Sep 30, 2023 | 2,132 | 572 | 36.67% |
| Jun 30, 2023 | 2,015 | 570 | 39.45% |
| Mar 31, 2023 | 1,846 | 537 | 41.02% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Sep 30, 2022 | 1,560 | 424 | 37.32% |
| Jun 30, 2022 | 1,445 | 416 | 40.43% |
| Mar 31, 2022 | 1,309 | 438 | 50.29% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Sep 30, 2021 | 1,136 | 424 | 59.55% |
| Jun 30, 2021 | 1,029 | 393 | 61.79% |
| Mar 31, 2021 | 871 | 292 | 50.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 6,772 |
| Moderna | 5,800 |
| Incyte | 2,617 |
| Insmed | 1,271 |
| Ionis Pharmaceuticals | 1,069 |
| Ascendis Pharma | 1,017 |
| Revolution Medicines | 809 |
| Roivant Sciences | 750 |
GMAB News
- 1 day ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 - GlobeNewsWire
- 1 day ago - Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside - Benzinga
- 5 days ago - Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study - Reuters
- 5 days ago - Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Business Wire
- 8 days ago - Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - Genmab: AI Partnership And Clinical Data Fuel Growth - Seeking Alpha
- 15 days ago - Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Business Wire
- 17 days ago - Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire